<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03453190</url>
  </required_header>
  <id_info>
    <org_study_id>WIRB1180837</org_study_id>
    <nct_id>NCT03453190</nct_id>
  </id_info>
  <brief_title>Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis</brief_title>
  <official_title>Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington Dermatology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington Dermatology Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers want to find out if giving the drug Apremilast in combination with Clobetasol&#xD;
      spray can help people clear their moderate to severe plaque psoriasis quicker than if&#xD;
      Apremilast is used by itself.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People over age 18 with moderate to severe plaque psoriasis who choose to be in the study and&#xD;
      pass the four week screening period will visit the study center about 8 times over about 16&#xD;
      weeks. All participants will be given Apremilast, a pill that you take in the morning and at&#xD;
      night, and which studies have shown may reduce inflammation and improve psoriasis symptoms.&#xD;
      All participants will also be given Clobetasol to spray twice daily for two weeks, then once&#xD;
      daily for two weeks, then every other day for two weeks. All drugs and study visits are at no&#xD;
      cost to participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 25, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area Severity Index (PASI)</measure>
    <time_frame>16 weeks</time_frame>
    <description>PASI is a measure of psoriatic disease severity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Psoriasis Patients on Comb. Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be given Apremilast 30 mg bid and Clobetasol Spray 0.05 % bid on a tapering schedule over 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Apremilast and Clobetasol</intervention_name>
    <description>Patients will receive apremilast and clobetasol with tapering dosages over 16 weeks.</description>
    <arm_group_label>Psoriasis Patients on Comb. Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be in general good health (except for disease under study) as judged by the&#xD;
             Sponsor Investigator, based on medical history, and physical examination. (NOTE: The&#xD;
             definition of good health means a subject does not have uncontrolled significant&#xD;
             co-morbid conditions).&#xD;
&#xD;
          2. Females of childbearing potential (FCBP)â€  must have a negative pregnancy test at&#xD;
             Screening and Baseline.&#xD;
&#xD;
             Option 1: Any one of the following highly effective methods: hormonal contraception&#xD;
             (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device&#xD;
             (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom&#xD;
             (latex condom or nonlatex condom not made out of natural [animal] membrane [for&#xD;
             example, polyurethane]; plus one additional barrier method: (a) diaphragm with&#xD;
             spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with&#xD;
             spermicide&#xD;
&#xD;
          3. Plaque psoriasis with at least 10% body surface area (BSA) involving the body with or&#xD;
             without scalp lesions in adults aged 18 years and older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other than disease under study, any clinically significant (as determined by the&#xD;
             Sponsor Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric,&#xD;
             hepatic, renal, hematologic, immunologic disease, or other major disease that is&#xD;
             currently uncontrolled.&#xD;
&#xD;
          2. Any condition which would place the subject at unacceptable risk if he/she were to&#xD;
             participate in the study.&#xD;
&#xD;
          3. Prior history of suicide attempt at any time in the subject's life time prior to&#xD;
             screening or baseline, or major psychiatric illness requiring hospitalization within&#xD;
             the last 3 years.&#xD;
&#xD;
          4. Pregnant or breast feeding.&#xD;
&#xD;
          5. Active substance abuse or a history of substance abuse within 6 months prior to&#xD;
             Screening.&#xD;
&#xD;
          6. Malignancy or history of malignancy, except for:&#xD;
&#xD;
               1. treated [ie, cured] basal cell or squamous cell in situ skin carcinomas;&#xD;
&#xD;
               2. treated [ie, cured] cervical intraepithelial neoplasia (CIN) or carcinoma in situ&#xD;
                  of cervix with no evidence of recurrence within the previous 5 years.&#xD;
&#xD;
          7. Use of any investigational drug within 4 weeks prior to baseline, or 5&#xD;
             pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).&#xD;
&#xD;
          8. Prior treatment with apremilast.&#xD;
&#xD;
          9. Concomitant use of drugs that treat psoriasis including but not limited to&#xD;
             methotrexate, acitretin, cyclosporine within 4 weeks of baseline.&#xD;
&#xD;
         10. Adalimumab, etanercept, efalizumab, infliximab, or certolizumab pegol within 12 weeks&#xD;
             prior to baseline.&#xD;
&#xD;
         11. Alefacept, briakinumab, ixekizumab, brodalumab or ustekinumab within 24 weeks prior to&#xD;
             baseline.&#xD;
&#xD;
         12. Use of phototherapy within 4 weeks prior to baseline&#xD;
&#xD;
         13. Plaque-type psoriasis with BSA&lt;10%&#xD;
&#xD;
         14. Psoriasis predominantly involving the face or folds (groin or axilla)&#xD;
&#xD;
         15. Psoriasis only of the palms/soles, pustular or other forms of psoriasis&#xD;
&#xD;
         16. Concurrent skin or systemic infection&#xD;
&#xD;
         17. History of intolerance to topical steroids or apremilast.&#xD;
&#xD;
         18. Topical therapy within 2 weeks of baseline (including but not limited to topical&#xD;
             corticosteroids, topical retinoids or vitamin D analog preparations, tacrolimus,&#xD;
             pimecrolimus, or anthralin/dithranol). Exceptions: Clobetasol Spray 0.05%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ronald Prussick, MD</last_name>
    <phone>3019843000</phone>
    <email>drprussick@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vicki Smith</last_name>
    <phone>3019843000</phone>
    <email>wdcderm22@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington Dermatology Center</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicki Smith</last_name>
      <phone>301-984-3000</phone>
      <email>wdcderm22@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ronald Prussick, M.D.</last_name>
      <phone>3019843000</phone>
      <email>drprussick@aol.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ronald Prussick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Menter A. Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial. Cutis. 2007 Nov;80(5 Suppl):12-9.</citation>
    <PMID>18154219</PMID>
  </reference>
  <reference>
    <citation>Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012 Aug 25;380(9843):738-46. doi: 10.1016/S0140-6736(12)60642-4. Epub 2012 Jun 29.</citation>
    <PMID>22748702</PMID>
  </reference>
  <reference>
    <citation>Beutner K, Chakrabarty A, Lemke S, Yu K. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol. 2006 Apr;5(4):357-60.</citation>
    <PMID>16673804</PMID>
  </reference>
  <reference>
    <citation>Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S171-81. Review.</citation>
    <PMID>16488339</PMID>
  </reference>
  <reference>
    <citation>Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005 Jan;141(1):82-4.</citation>
    <PMID>15655149</PMID>
  </reference>
  <reference>
    <citation>Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44.</citation>
    <PMID>357213</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2018</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington Dermatology Center</investigator_affiliation>
    <investigator_full_name>Ronald Prussick</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03453190/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

